Mutations in the Raf-MEK-ERK mitogen-activated protein kinase (MAPK) cell proliferation signalling pathway, including BRAF, NRAS and KIT mutations, are frequently detected in patients with malignant melanoma; the BRAF mutation rate in the Japanese population is about 30% [4]. This evidence concerns the gene MAP2K7 and melanoma.